LLY
85

Eli Lilly and Company

Generating destination analysis

85
True North

Eli Lilly and Company

LLY

Biotech & Genomics
Mixed
Favorable
NYSE

Compass Direction

Earnings Intelligence
AI-Powered

Loading earnings analysis...

Compass Score

85Favorable

Unlock Full LLY Analysis

Upgrade

Key Numbers

Market Cap

$750B

P/E

65

Revenue Growth

+32.0%

Gross Margin

N/A

ROE

N/A

About Eli Lilly and Company

Eli Lilly and Company (LLY) is a mega-cap NYSE-listed company in the pharma space, blending biotech and genomics initiatives alongside its core business operations. Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs. Valued at 65x trailing earnings with a $750B market capitalization, Eli Lilly and Company has delivered rapid top-line expansion with revenue moving +32% over the past year.

Expert Coverage

Loading coverage...

Price & Technical Analysis

Price50 DMA200 DMA

Price vs 200DMA

DMA Convergence

50 DMA

200 DMA

Rating last updated: 2026-03-28

More in Biotech & Genomics

Unlock Full Analysis for LLY

Destination analysis, price scenarios, earnings intelligence, and score breakdowns — all included with membership.